Yujiro Hata - Feb 1, 2024 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Signature
/s/ Jason Throne, as Attorney-in-Fact for Yujiro Hata
Stock symbol
IDYA
Transactions as of
Feb 1, 2024
Transactions value $
-$25,553
Form type
4
Date filed
2/5/2024, 06:05 PM
Previous filing
Jan 17, 2024
Next filing
Feb 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $2.71K +628 +0.09% $4.31 679K Feb 1, 2024 Direct
transaction IDYA Common Stock Sale -$28.1K -624 -0.09% $45.00 678K Feb 1, 2024 Direct F1
transaction IDYA Common Stock Sale -$180 -4 0% $45.01 678K Feb 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (right to buy) Options Exercise $0 -628 -0.19% $0.00 324K Feb 1, 2024 Common Stock 628 $4.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023.
F2 The shares subject to the option are fully vested and exercisable.